Company
Syntara Ltd
ASX:PXS
Syntara Ltd is a clinical-stage drug development company focused on the development of novel therapeutics aimed at correcting extracellular matrix (ECM) dysfunction. This will lead to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
175 stories · page 8 of 9
Pharmaxis portfolio fires on all pistons as U.S. relations warm up
Strengthening relationships, a multi-pronged research program and an agenda for milestone payments have Pharmaxis in good shape.
ASX recovers as this medical play keeps shining
The Australian All Ordinaries rebounded today with strong performances from all sections except mining, where price woes continue to cause concern. This medical play added to the momentum for health stocks with another positive showing.
ASX bounces back as this medical play drives forward
The Australian All Ordinaries rebounded 2.3% today to 5,079 points with help from a strongly advancing pharmaceutical researcher.
Pharmaxis enhances outlook for cystic fibrosis treatment
Pharmaxis has received positive trial results for its cystic fibrosis treatment, Bronchitol, setting the company up to expand its marketing of the drug in Europe as a plan to penetrate the U.S. market develops.
Pharmaxis pumps up cash as partnerships and products add value
Pharmaxis Limited more than doubled its cash at bank year-on-year to A$50.3 million at the end of the September quarter as the company realised significant drug trialling and collaborative research milestones.
Pharmaxis Limited drug trials success builds product confidence
The successful clinical trial will enable one of the world’s 20 leading pharmaceutical companies, Boehringer Ingelheim, to proceed with further development of the program. Boehringer Ingelheim, a leader in cardiometabolic and respirat
Pharmaxis, Synairgen collaborate on pulmonary fibrosis treatment
The collaboration with Synairgen could accelerate development of the lung disease treatment while reducing risks on the path to value points. Pharmaxis has executed three deals in six months and is tapping into a rich seam of potential drug